Blood Cells – PharmaLive

Novartis’ crizanlizumab receives FDA Breakthrough Therapy designation for prevention of vaso-occlusive crises in sickle cell disease

Blood Cells, Blood Disorders, Blood Vessels, Breakthrough Therapy Designation, FDA, FDA/Regulatory, Red Blood Cell, Sickle Cell Disease

Novartis announced that the U.S. Food and Drug Administration granted crizanlizumab (SEG101) Breakthrough Therapy designation for the prevention of vaso-occlusive crises in patients of all genotypes with sickle cell disease.

January 8, 2019/by PR Newswire

Magenta Therapeutics and Heidelberg Pharma Team Up for Bone Marrow Transplants

Abstracts, Autoimmune Diseases, Blood Cancers, Blood Cells, Bone Marrow Transplants, Genetic Diseases, Google, Investors, Stem Cells

Cambridge, Massachusetts-based Magenta Therapeutics is teaming up with Ladenburg, Germany-based Heidelberg Pharma GmbH to improve curative bone marrow transplantation.

March 6, 2018/by BioSpace